| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -16,750 | -18,550 | -17,560 | -6,840 | -2,340 |
| Net Income Growth | +9.70% | -5.64% | -156.73% | -192.31% | unch |
Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.
Fiscal Year End Date: 12/31